ADVA
14.4.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today extended its Ensemble Sync Director GNSS assurance software to integrate any third-party vendor’s GNSS receiver observables at scale. A key pillar of ADVA’s aPNT+™ technology, Ensemble Sync Director is now vendor-agnostic, providing defense-in-depth, resilient and assured PNT for more customers than ever before. Ensemble Sync Director can now transparently show and analyze GNSS observables from third-party receivers in even the largest deployments. This is key as synchronization based on satellite signals is vulnerable to failure, interference and cyberthreats, and so network operators urgently need to protect their critical timing with continuous monitoring and assurance. Now, they have the power to remotely detect issues with GNSS receivers from any vendor, helping to maintain high-quality timing performance, avoid disruptions and reduce operating costs.
“The number of GNSS devices in use is growing by the day, with many networks now relying on hundreds or even thousands of receivers. At the same time, the risks to satellite-based timing have never been greater, including the rising threat of jamming and spoofing attacks. By extending our GNSS assurance application capabilities beyond our own timing equipment, we’re empowering many more customers to protect their mission-critical synchronization in new or deployed infrastructure,” said Gil Biran, GM of Oscilloquartz, ADVA. “Our Ensemble Sync Director, with comprehensive GNSS assurance for both resilient and assured PNT, provides a simple, scalable and highly cost-efficient way to harness our unique experience and expertise in managing a huge number of GNSS-dependent network elements.”
ADVA’s Oscilloquartz GNSS assurance solution for integrating third-party receiver data is an extension of its Sync Director application, part of the Ensemble Controller network management platform. It offers centralized in-service monitoring and analysis of GNSS status and reliability as well as AI/ML-based prediction and prevention of obstruction, jamming and spoofing. Using topology and timing chain mapping, Ensemble Sync Director displays the entire timing network infrastructure in a user-intuitive graphical format. ADVA’s GNSS assurance capabilities are aligned with the goals of the DHS Resilient PNT Conformance Framework and future IEEE P1952 Resilient PNT Standard to protect critical infrastructure. Available from ADVA Professional Services, the new solution is ideal for network operators in telecoms, power utilities, financial trading, data centers and more, who need to ensure robust, reliable and resilient GNSS timing. It also offers significant value to system integrator vendors looking to add vital GNSS protection capabilities to their synchronization portfolio.
“People are increasingly aware of the risk factors affecting GNSS-reliant systems, as well as the heavy price that disruption can bring. Whether they are addressing PNT regulations or responding to the precarious geopolitical situation, more and more network operators are looking to take urgent action to safeguard their timing architectures with resilient and assured PNT capabilities. That’s why we’re extending our GNSS assurance software with real-time monitoring to integrate third-party timing receiver data and enable more customers to proactively protect their critical infrastructure,” commented Michael Port, VP of product line management at ADVA. “Scalable and easy to implement, our new offering adds instant value. What’s more, Ensemble Sync Director supports open integration, enabling end-to-end vendor-agnostic sync and timing network management.”
Further information is available in these slides: https://adva.li/third-party-gnss-assurance-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005726/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
